Peptide · Fact sheet

GHRP-2

Also known as growth hormone-releasing peptide-2 · pralmorelin

GHRP-2 is an experimental growth-hormone secretagogue that activates the ghrelin receptor. It is not FDA approved, and small human physiology studies do not prove that it builds muscle, improves recovery, or slows aging.

Not FDA approvedEarly human evidence

What is GHRP-2?

GHRP-2 is a synthetic six-amino-acid peptide that activates the growth-hormone secretagogue receptor, also called the ghrelin receptor.

It can increase growth-hormone release and appetite, but a hormone spike is a biomarker—not a demonstrated body-composition or performance outcome.

Benefits & claims

It is promoted online for muscle growth, recovery, fat loss, sleep, and anti-aging, sometimes alongside other growth-hormone-pathway peptides.

Human studies more clearly show appetite and hormone effects than the desired performance outcomes used in marketing.

What the evidence supports

  • Small controlled studies show increased growth hormone and short-term food intake.
  • Those biological effects do not demonstrate improved muscle mass, strength, recovery, or healthspan.
Research areas
  • Growth-hormone release
  • Appetite and food intake
  • Endocrine testing and physiology
  • Critical-illness metabolism in older research
  • Growth-hormone and ghrelin-receptor physiology
  • Appetite and metabolic research

Dosage & frequency

Human study context

GHRP-2 has human hormone-response research, but there is no established FDA-approved muscle, recovery, or anti-aging regimen.

Acute appetite and GH-response crossover experiment

Seven lean healthy men

Amount
1 mcg/kg/hour
Frequency
One 270-minute experimental infusion
Route studied or labeled
Subcutaneous infusion

Acute food-intake and hormone measurements; not an approved repeated-use regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Diagnostic or experimental endocrine responses do not establish long-term treatment benefit.

Interactions & precautions

  • Human hormone-response studies do not establish a safe interaction profile with other GH or endocrine treatments.

What is still unresolved

  • The clinical value and long-term metabolic risks of repeated use remain uncertain.

Side effects & risks

  • FDA identifies potential immune reactions, aggregation, peptide impurities, and complexity from an unnatural amino acid.
  • FDA notes reports of increased insulin requirements, infection, pancreatitis, and deaths in critically ill study participants, while stating that causality was not established.
  • The peptide can increase appetite and may affect glucose and endocrine signaling in ways that conflict with popular body-composition claims.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Small controlled human studies establish short-term effects on growth hormone and food intake. They do not establish meaningful muscle growth, recovery, fat loss, sleep, or longevity benefits.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 5 sourced accounts by reported effect.

Appetite: reported experiences

Positive account · personal report

More refreshing sleep and slight hunger

A commenter in the same discussion described easier sleep, waking refreshed, slightly greater appetite and modestly better workout recovery during about two months of nasal GHRP-2 exposure.

Reported use in this account

Product
Product described as GHRP-2
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Intranasal
Duration
About two months

The formulation was unverified and there were no sleep or recovery measurements. This cannot be transferred to other routes or products.

Read the original account
Mixed account · personal report

Sleep benefit varied; hunger sometimes disrupted it

A different commenter described inconsistent sleep improvement across several growth-hormone secretagogues, with GHRP-2 and GHRP-6 sometimes worsening sleep through hunger.

Amount, frequency, route and duration could not be confirmed for this account.

This is a retrospective comparison of multiple unverified exposures, without separate records for each compound.

Read the original account
Negative account · personal report

Sweating and weakness after a combined first exposure

An author reported sweating, weakness and feeling unwell minutes after a first GHRP-2 and modified GRF exposure, followed later by hunger.

Reported use in this account

Product
Product described as GHRP-2
Amount
100 mcg
Frequency
One reported administration
Route
Not specified clearly
Duration
One reported administration

Other exposures described: Modified GRF (1-29), reported at 100 mcg in the same event; Testosterone cypionate; hCG; Anastrozole; Cabergoline; Tadalafil

The same author identified a ketogenic diet and several other exposures in a later post. No glucose result or administration route was stated; the account does not establish hypoglycemia or isolate GHRP-2 as the cause.

Read the combined-exposure account

Approval status

GHRP-2 is not FDA approved. FDA places GHRP-2 for injectable and nasal routes in a compounding category associated with potential significant safety risks.

No active FDA approval path identified

GHRP-2 has small human physiology studies, but no FDA-approved product and no cited active approval program for muscle, recovery, appetite, or aging uses.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term human safety
  • Whether any meaningful muscle, strength, recovery, sleep, or body-composition benefit exists
  • Risks of combinations with other growth-hormone-pathway substances
  • Product identity and quality outside an approved drug application

Summary

GHRP-2 changes hormone levels in small human studies. That does not establish better muscle growth or performance.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. pubmedGHRP-2 food-intake study in healthy men

    Small controlled physiology study of growth hormone and short-term food intake.

  3. pubmedRandomized GHRP-2 appetite study

    Small double-blind study showing exposure-related food-intake and hormone effects, not muscle benefit.

  4. pubmedRandomized GHRP-2 endocrine physiology study

    Controlled hormone-secretion study in young men; it did not test performance outcomes.

How we assess sources · Suggest a correction